FDA Slaps Aegerion Pharmaceuticals, Inc. CEO For "Serious" Violations Of Drug Promotion Law Following CNBC Interview

The FDA scolded Aegerion Pharmaceuticals (AEGR_) CEO Marc Beer in a sharply worded warning letter Friday for making exaggerated and unsubstantiated claims about the benefits of the company's cholesterol-lowering drug Juxtapid during two separate appearances on CNBC. Beer's on-air statements about Juxtapid provided evidence that Aegerion was marketing the drug for unapproved uses -- a "serious" violation of FDA law, regulators said. During interviews on CNBC's "Fast Money" program, Beer suggesting treatment with Juxtapid prevents heart attacks and extends the lives of patients with familial homozygous hyercholesterolemia (HoFH), a rare genetic disease which causes the build up of extremely high levels of cholesterol in the blood.

Help employers find you! Check out all the jobs and post your resume.